CN Patent

CN115227710A — 用于在对象中调节smn2剪接的组合物和方法

Assigned to Bojian Massachusetts Co ltd · Expires 2022-10-25 · 4y expired

What this patent protects

本发明公开了用于调节对象中的SMN2mRNA剪接的化合物、组合物和方法。还提供了所公开的化合物和组合物用于生产药物的用途，所述药物用于治疗疾病和病症，包括脊髓性肌萎缩症。

USPTO Abstract

本发明公开了用于调节对象中的SMN2mRNA剪接的化合物、组合物和方法。还提供了所公开的化合物和组合物用于生产药物的用途，所述药物用于治疗疾病和病症，包括脊髓性肌萎缩症。

Drugs covered by this patent

Patent Metadata

Patent number
CN115227710A
Jurisdiction
CN
Classification
—
Expires
2022-10-25
Drug substance claim
No
Drug product claim
No
Assignee
Bojian Massachusetts Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.